BNP Paribas Financial Markets’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $528 | Sell |
46
-12
| -21% | -$96 | ﹤0.01% | 5671 |
|
|
2026
Q1 | $274 | Buy |
58
+12
| +26% | +$73 | ﹤0.01% | 5605 |
|
|
2025
Q4 | $832 | Sell |
46
-4
| -8% | -$60 | ﹤0.01% | 5420 |
|
|
2025
Q3 | $716 | Hold |
50
| – | – | ﹤0.01% | 5274 |
|
|
2025
Q2 | $386 | Hold |
50
| – | – | ﹤0.01% | 5240 |
|
|
2025
Q1 | $297 | Sell |
50
-11
| -18% | -$96 | ﹤0.01% | 5179 |
|
|
2024
Q4 | $812 | Buy |
61
+5
| +9% | +$53 | ﹤0.01% | 5111 |
|
|
2024
Q3 | $455 | Sell |
56
-36,668
| -100% | -$314K | ﹤0.01% | 4010 |
|
|
2024
Q2 | $312K | Buy |
36,724
+21,401
| +140% | +$322K | ﹤0.01% | 2897 |
|
|
2024
Q1 | $266K | Buy |
15,323
+3,473
| +29% | +$61.7K | ﹤0.01% | 3155 |
|
|
2023
Q4 | $152K | Buy |
11,850
+11,061
| +1,402% | +$258K | ﹤0.01% | 3297 |
|
|
2023
Q3 | $29.2K | Sell |
789
-2,237
| -74% | -$99.6K | ﹤0.01% | 3530 |
|
|
2023
Q2 | $122K | Sell |
3,026
-7,290
| -71% | -$412K | ﹤0.01% | 3198 |
|
|
2023
Q1 | $748K | Buy |
10,316
+6,030
| +141% | +$585K | ﹤0.01% | 2503 |
|
|
2022
Q4 | $351K | Sell |
4,286
-3,645
| -46% | -$380K | ﹤0.01% | 2767 |
|
|
2022
Q3 | $749K | Buy |
7,931
+6,856
| +638% | +$770K | ﹤0.01% | 2694 |
|
|
2022
Q2 | $209K | Buy |
1,075
+541
| +101% | +$88.3K | ﹤0.01% | 3067 |
|
|
2022
Q1 | $124K | Sell |
534
-1,434
| -73% | -$457K | ﹤0.01% | 3302 |
|
|
2021
Q4 | $775K | Buy |
1,968
+804
| +69% | +$338K | ﹤0.01% | 2764 |
|
|
2021
Q3 | $521K | Buy |
1,164
+317
| +37% | +$114K | ﹤0.01% | 2732 |
|
|
2021
Q2 | $329K | Sell |
847
-595
| -41% | -$212K | ﹤0.01% | 2717 |
|
|
2021
Q1 | $518K | Sell |
1,442
-2,808
| -66% | -$1.24M | ﹤0.01% | 2549 |
|
|
2020
Q4 | $2.09M | Buy |
4,250
+3,565
| +520% | +$1.65M | ﹤0.01% | 1614 |
|
|
2020
Q3 | $222K | Buy |
685
+368
| +116% | +$125K | ﹤0.01% | 2716 |
|
|
2020
Q2 | $115K | Sell |
317
-785
| -71% | -$198K | ﹤0.01% | 2713 |
|
|
2020
Q1 | $234K | Buy |
1,102
+846
| +330% | +$269K | ﹤0.01% | 2782 |
|
|
2019
Q4 | $105K | Sell |
256
-64
| -20% | -$22.1K | ﹤0.01% | 3269 |
|
|
2019
Q3 | $113K | Buy |
320
+118
| +58% | +$44K | ﹤0.01% | 3060 |
|
|
2019
Q2 | $102K | Sell |
202
-163
| -45% | -$115K | ﹤0.01% | 3028 |
|
|
2019
Q1 | $362K | Buy |
365
+350
| +2,333% | +$325K | ﹤0.01% | 2310 |
|
|
2018
Q4 | $12.9K | Sell |
15
-52
| -78% | -$48.3K | ﹤0.01% | 3262 |
|
|
2018
Q3 | $69.2K | Buy |
67
+4
| +6% | +$3.91K | ﹤0.01% | 2923 |
|
|
2018
Q2 | $58K | Sell |
63
-208
| -77% | -$223K | ﹤0.01% | 3055 |
|
|
2018
Q1 | $264K | Buy |
271
+43
| +19% | +$39.2K | ﹤0.01% | 2639 |
|
|
2017
Q4 | $103K | Buy |
228
+130
| +133% | +$48K | ﹤0.01% | 3282 |
|
|
2017
Q3 | $40.4K | Sell |
98
-6
| -6% | -$2.26K | ﹤0.01% | 3257 |
|
|
2017
Q2 | $36.4K | Buy |
104
+99
| +1,980% | +$38.1K | ﹤0.01% | 3352 |
|
|
2017
Q1 | $2.71K | Sell |
5
-47
| -90% | -$19.5K | ﹤0.01% | 3455 |
|
|
2016
Q4 | $18.5K | Sell |
52
-12
| -19% | -$5.08K | ﹤0.01% | 3215 |
|
|
2016
Q3 | $34.4K | Buy |
64
+27
| +73% | +$14.7K | ﹤0.01% | 2606 |
|
|
2016
Q2 | $21.1K | Buy |
+37
| New | +$17.8K | ﹤0.01% | 2567 |
|
|
2016
Q1 | – | Sell |
-155
| Closed | -$103K | – | 2693 |
|
|
2015
Q4 | $103K | Buy |
155
+14
| +10% | +$10.6K | ﹤0.01% | 2319 |
|
|
2015
Q3 | $111K | Buy |
141
+93
| +194% | +$113K | ﹤0.01% | 2329 |
|
|
2015
Q2 | $63.6K | Buy |
48
+42
| +700% | +$48.2K | ﹤0.01% | 2344 |
|
|
2015
Q1 | $6.69K | Buy |
+6
| New | +$3.96K | ﹤0.01% | 2984 |
|
Other funds holding ATRA
VCM
SCA
VFT
BNP Paribas Financial Markets's ATRA Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Atara Biotherapeutics (ATRA) stake by 21% in Q2 2026, selling an estimated $96 and leaving 46 shares worth $528. The position accounts for ﹤0.01% of the portfolio, ranked #5671.
BNP Paribas Financial Markets first reported a position in ATRA in Q1 2015 and has held it in 45 quarters since. The position peaked at $2.09M in Q4 2020. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.
- BNP Paribas Financial Markets held 46 shares of Atara Biotherapeutics worth $528 as of Q2 2026.
- BNP Paribas Financial Markets sold 12 Atara Biotherapeutics shares in Q2 2026, an estimated $96.
- Atara Biotherapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5671 holding.
- BNP Paribas Financial Markets first reported a position in Atara Biotherapeutics in Q1 2015 and has held it in 45 quarters since.
- BNP Paribas Financial Markets's Atara Biotherapeutics position peaked at $2.09M in Q4 2020.
- 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.